Sensitizers and radiation dose fractionation: results and interpretations
Journal Article
·
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
Misonidazole is generally regarded as having been a clinical failure as a radiation sensitizer. It is hoped that the newer sensitizers SR-2508 and Ro 03-8799 will give better results because single dose studies with animal tumors have indicated that these two drugs give higher enhancement ratios than misonidazole at clinically tolerated doses. Other factors may also have influenced the clinical efficacy of misonidazole, however, particularly reoxygenation during the course of the fractionated treatments. In this paper reoxygenation in animal tumors and experimental studies in which fractionated radiation doses have been combined with sensitizers are reviewed. It is concluded that, even for dose fractions of 2 Gy, reoxygenation may not completely eliminate the influence of hypoxic cells on tumor response, when large total doses are given. Problems associated with tumor heterogeneity are also discussed to highlight the desirability of selecting the most suitable patients for clinical studies. Poorly reoxygenating tumors, rapidly growing tumors and tumors in patients in whom oxygen delivery to tissue is compromised are those whose control is most likely to be improved by combining radiation sensitizers with conventional treatment. However effective sensitizers should also allow fractionation schedules to be modified, to achieve a therapeutic gain, by taking advantage of differences in repair or repopulation between the tumor and critical normal tissue, without having to consider possible detrimental effects on reoxygenation. 39 references.
- Research Organization:
- Ontario Cancer Institute, Toronto
- OSTI ID:
- 5005350
- Journal Information:
- Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 7; ISSN IOBPD
- Country of Publication:
- United States
- Language:
- English
Similar Records
Hypoxic cell radiosensitizers: expectations and progress in drug development
Evaluation of nitroimidazole hypoxic cell radiosensitizers in a human tumor cell line high in intracellular glutathione
Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)
Journal Article
·
Thu Jan 31 23:00:00 EST 1985
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:5652626
Evaluation of nitroimidazole hypoxic cell radiosensitizers in a human tumor cell line high in intracellular glutathione
Journal Article
·
Fri Mar 31 23:00:00 EST 1989
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6253742
Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)
Journal Article
·
Thu Sep 01 00:00:00 EDT 1988
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6699515
Related Subjects
560151* -- Radiation Effects on Animals-- Man
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANIMALS
ANTINEOPLASTIC DRUGS
AZOLES
CHEMICAL REACTIONS
DISEASES
DRUGS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
MAMMALS
MICE
MISONIDAZOLE
NEOPLASMS
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
OXIDATION
OXYGEN ENHANCEMENT RATIO
PATIENTS
RADIOSENSITIVITY EFFECTS
RADIOSENSITIZERS
RODENTS
VERTEBRATES
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANIMALS
ANTINEOPLASTIC DRUGS
AZOLES
CHEMICAL REACTIONS
DISEASES
DRUGS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
MAMMALS
MICE
MISONIDAZOLE
NEOPLASMS
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
OXIDATION
OXYGEN ENHANCEMENT RATIO
PATIENTS
RADIOSENSITIVITY EFFECTS
RADIOSENSITIZERS
RODENTS
VERTEBRATES